John Blankenhorn

John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend

By John Blankenhorn, InvestorPlace Contributor

Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today.

The 3 Best Machine Learning Stocks to Buy Now: September 2023

By John Blankenhorn, InvestorPlace Contributor

The AI revolution is bringing big gains to machine learning stocks. Here are three of the best to buy right now.

Sky’s the Limit: 3 Stocks Ready to Rocket as Flying Cars Surge

By John Blankenhorn, InvestorPlace Contributor

These three flying car stocks are pushing aggressive timetables with proven aircraft. They may be taking you to your next meeting.

Robo-Lab Stocks: 3 Robotics Companies Changing the Research Game

By John Blankenhorn, InvestorPlace Contributor

Robotics will upend laboratory research just as they upended factories. Bet on the future with these 3 robo-lab company stocks.

3 Beaten-Down Biotech Stocks Bound for a Bounce Back

By John Blankenhorn, InvestorPlace Contributor

Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs.

Load More